DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit

DermTech, Inc. (NASDAQ:DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the presentation of a precision medicine focused session at the fourth annual Dermatology Drug Development Summit. Held virtually this year, the Dermatology Drug Development Summit is the only industry-focused meeting dedicated to innovating, accelerating, and sharing pharmaceutical best practice on the development and bringing to market of new dermatological drugs, in the treatment of high unmet need. 

The session, titled, “Stickering it to Skin Disease: The Drive for Precision and Personalized Dermatology,” presented by Michael D. Howell, PhD, Chief Scientific Officer of DermTech, explored the current approaches to precision medicine in dermatology and the integration of precision medicine and biomarker approaches in clinical trials. Howell reviewed DermTech’s proprietary Smart Sticker platform and its use in early detection of skin cancers including cutaneous melanoma. Howell also discussed how non-invasive skin sampling can enhance precision medicine by detecting genomic and proteomic changes in the skin without the need for a skin biopsy. Finally, Howell discussed how the expanded use of DermTech’s breakthrough tool can guide personalized approaches to disease diagnosis and intervention.

The presentation is available for viewing here.

“The Dermatology Drug Development Summit brings together leaders in academia, government, and industry with a goal of driving innovative medicine in dermatology. The DermTech Smart Sticker is an innovative platform that non-invasively assesses genomic and proteomic changes in the skin before those changes can be visually detected. With more than 3,000 potentially identifiable dermatological diseases and an ever increasing armamentarium of therapies, the Smart Sticker technology enables innovative approaches to precision and personalized dermatology,” commented Howell.

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.

Forward-looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products, including the Smart Sticker platform, and the market opportunity therefor. These forward-looking statements involve

Read more

Development of new stem cell type may lead to advances in regenerative medicine

IMAGE

IMAGE: Drs. Jun Wu, Leqian Yu, Yulei Wei and colleagues isolated a new type of pluripotent stem cell from mice, horses, and humans, named XPSCs, which are capable of generating chimeras…
view more 

Credit: Photo illustration by Leqian Yu

DALLAS – Dec. 3, 2020 – A team led by UT Southwestern has derived a new “intermediate” embryonic stem cell type from multiple species that can contribute to chimeras and create precursors to sperm and eggs in a culture dish.

The findings, published online this week in Cell Stem Cell, could lead to a host of advances in basic biology, regenerative medicine, and reproductive technology.

Cells in early embryos have a range of distinct pluripotency programs, all of which endow the cells to create various tissue types in the body, explains study leader Jun Wu, Ph.D., assistant professor of molecular biology. A wealth of previous research has focused on developing and characterizing “naïve” embryonic stem cells (those about four days post-fertilization in mice) and “primed” epiblast stem cells (about seven days post-fertilization in mice, shortly after the embryo implants into the uterus).

However, says Wu, there’s been little progress in deriving and characterizing pluripotent stem cells (PSCs) that exist between these two stages – largely because researchers have not been able to develop a paradigm for maintaining cells in this intermediate state. Cells in this state have been thought to possess unique properties: the ability to contribute to intraspecies chimeras (organisms that contain a mix of cells from different individuals of the same species) or interspecies chimeras (organisms that contain a mix of cells from different species) and the ability to differentiate into primordial germ cells in culture, the precursors to sperm and eggs.

For this study, the researchers successfully created intermediate PSCs, which they named “XPSCs” from mice, horses, and humans.

Wu says that these results could eventually lead to an array of advances in both basic and applied research. For example, looking at gene activity in XPSCs from different species and interspecies chimeras could help researchers understand which signatures have been conserved through evolution. Examining the communication between cells in chimeras may help scientists identify strategies that could be used to accelerate the development of tissues and organs from stem cells used for transplantation. And using chimera-derived primordial germ cells to create sperm and eggs could aid in preserving endangered animal species and advancing infertility treatments.

“These XPSCs have enormous potential. Our study helps open the door to each of these possibilities,” says Wu, who is a Virginia Murchison Linthicum Scholar in Medical Research.

Wu notes that developing XPSCs presented a special challenge because the conditions that keep naïve PSCs in a stable state are exactly the opposite from those that stabilize primed PSCs. While culture conditions for naïve PSCs must activate a WNT cell-signaling pathway and suppress the FGF and TGF-ß pathways, the conditions to maintain primed PSCs must suppress WNT and activate FGF and TGF-ß.

Aiming for the preferred environment for XPSC derivation, Wu and his

Read more

Global Ophthalmic Medicine Market 2020 Size, Market Share, Key Players, Segmentation Development and Forecast by 2025

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (CDN Newswire via Comtex) —
The report entitled Global Ophthalmic Medicine Market 2020 by Manufacturers, Type and Application, Forecast to 2025 compiled by MarketQuest.biz presents a new market research analysis that offers a detailed evaluation of the business vertical and a brief overview of the industry segments. The report includes an elemental introduction to the industry, market overview, scope, and product specification. The report aims to target the major images related to market growth, major types, and various end users applicable, regional analysis, productivity structure, current, and future market situation. The report provides a determined perception of the popular market situation that also covers market size in terms of value and volume. Important segment classification of this market includes global Ophthalmic Medicine market-leading players, major geographical regions, product types, and applications.

The report describes the growth of the market such as manufacturers, market size, types, applications, and regions. The report highlights key factors driving and restraining market growth. The research portrays previous and forecasts information in the form of graphical representation. Factors that are encouraging the growth of a specific type of product category and factors that are motivating the status of the market are further included in this report. A comprehensive study of the market is done to recognize the several applications of the features of products and usage.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT:https://www.marketquest.biz/sample-request/20234

The major players who are leading the market throughout the globe are: Novaliq, Mentholatum, Chengdu Kanghong Pharmaceutical Group, Shenyang Xingqi Pharmaceutical Co.,Ltd., Alcon NV, Zhejiang Shapuaisi Pharmaceutical, Bausch Health, Santen Pharmaceutica

Moreover, the report concentrates on global higher leading business players with their details such as company profiles, product picture and specifications, sales, market share, and association information. Additionally, developing strategies and programs are addressed as well as manufacturing methods and cost formations are included. The research contains an analysis of the strategies of major competitors. Elements such as production capacity, price, demand, supply chain/logistics, profit/loss, material parameters/specifications, and the growth factor have been reviewed in the report.

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including: Anti-fatigue and Dryness, Cataract, Anti-infective

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share, and growth rate of each type, primarily split into: Eye Drops, Eye Ointment, Gelling Agent, Tablet, Injection

Keeping the regional landscape of the global Ophthalmic Medicine market in mind, this industry is segmented into: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast

Read more

AI-based earlier medicine development leveraging TWCC HPC to aid cancer prediction research

AI-based earlier medicine development leveraging TWCC HPC to aid cancer prediction research

Artificial Intelligence (AI) is shaping the future of global medical industries. The practice of medicine is changing with the development of AI methods of machine learning. As the increasing accuracy of predictive medicine, AI technology, based on analyzing patient’s medical records, is entailing predicting the probability of disease in order to either further diagnosis of disease allowing for the estimation of disease risks or significantly decrease the cost to deal with its impact upon the patient. The AI based prediction medicine is a new type of earlier medicine

Hsuan-Chia Yang, assistant professor of the Graduate Institute of Biomedical Informatics, Taipei Medical University, explains Prediction of Principle Health Threat (PROPHET) project. Led by Dr. Li Yu-Chuan, a pioneer of AI in Medicine and Medical Informatics Research, earlier medicine for fatal diseases is leveraging AI technology and data mining systems to provide a personal, real-time, accurate and manageable healthcare program. The PROPHET project provides the prediction of cancer risks and boosts the new business opportunity of start-ups. Taiwan Ministry of Science and Technology provides the funding support for this kind of projects.

Taking breast cancer detection as an example, there are 5 persons confirmed as positive out of every 1000 people screening. Applying the AI earlier medicine perdition method, the effective rate will be reduced to 5 confirmed out of 233 people check. There are 77% saving of breast cancer earlier diagnosis. The saved cost is obvious.

The basic of PROPHET project is making AI Bio-maker model using AI technology to screen cancer and provide the prediction. Transforming the patient medical records to time matrix data diagrams, the skill is setting to predict 10 kinds of cancer risks after one year time frame based on sequential medical records to develop a prediction model. Each prediction of various cancers could reach 85% AUROC (Area under the receiver operating characteristic) curves. Taiwan Healthcare insurance program preserves every citizen’s healthcare digital records of treatments and medicine usage. PROPHET takes this strength to analyze three-year personal data records to predict the cancer risks of next 12-month. These lower cost AI-based cancer predictions allow healthcare professions to participate in the decision about whether or not it is appropriate testing or detection priority for patients.

From the technical point of view, the dynamic prediction value of personal diseases is a time-dependent scenario. The time matrix combined with personal medicine usage records and various diseases could make a two dimensional health diagram. The vertical axis is thousands of variables including medicine usage, set of medical signs and symptoms. The horizontal axis is time listings based on week or month. There are about 250 thousand health diagrams to use in the AI training process to get effective prediction AI models. After requiring repeat fine-tuning in training new AI models of each cancer, it can be derived effective prediction models based on above AI Bio-marker.

However, the huge compute power to perform these AI training tasks requires huge support

Read more

Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development

CARLSBAD, Calif., Nov. 23, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH). ION455 is the second medicine for the treatment of NASH that Ionis has partnered with AstraZeneca. The companies have also partnered on ION839 (AZD2693), which is designed to inhibit the production of patatin-like phospholipase domain-containing 3 (PNPLA3) protein, a major genetic determinant of NASH progression. Separately, Ionis is also developing a wholly owned NASH program. ION224 is designed to reduce the production of DGAT2, or diacylglycerol acyltransferase 2, for treating patients with NASH. ION224 is one of more than 20 medicines in the growing Ionis-owned pipeline that the company is prioritizing and preparing for commercialization.

NASH is the most severe form of nonalcoholic fatty liver disease (NAFLD). It is related to the epidemic of obesity, pre-diabetes and diabetes. Unlike liver disease caused by alcohol consumption, NAFLD is the result of an accumulation of fat in the liver, which can lead to inflammation and cirrhosis, an advanced scarring of the liver that prevents the liver from functioning normally. About 20 percent of NASH patients are reported to develop cirrhosis and 30 to 40 percent of patients with NASH cirrhosis experience liver-related death.i Currently, a liver transplant is the only treatment for advanced cirrhosis and liver failure. Because of the high prevalence of NASH, it has recently become the third most common indication for liver transplantation in the U.S.

“Today, there are no FDA-approved medicines to specifically treat nonalcoholic steatohepatitis. However, due in large part to the progress made by our cardio-metabolic franchise, three Ionis-discovered novel medicines are now in development. These are encouraging advances that we hope will one day bring therapeutic benefit to patients who have limited treatment options,” said Brett P. Monia, Ph.D., Ionis’ chief executive officer. 

ION455 is the fourth medicine to reach development in partnership with AstraZeneca. Ionis earned $30 million from AstraZeneca for licensing ION455 and is eligible to earn up to $300 million in milestone payments plus royalties on net sales. AstraZeneca will have responsibility for further development of ION455, including regulatory filings, and commercialization.

In addition to NASH, Ionis and AstraZeneca are collaborating on potential treatments for kidney disease, cardiovascular disease and cancer.

Ionis’ Forward-looking Statement

This press release includes forward-looking statements regarding Ionis’ business and the therapeutic and commercial potential of ION455, ION839 (AZD2693), ION224 and Ionis’ technologies and products in development. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for

Read more

TFF Pharmaceuticals, Inc. and Augmenta Bioworks, Inc. Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies

Companies to collaborate in first-of-its-kind uses of Thin Film Freezing technology applied to monoclonal antibodies

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company, and Augmenta Bioworks, Inc., a biotechnology company enabling breakthroughs in medicine through immune profiling, today jointly announce that both companies have entered into a worldwide Joint Development and Collaboration Agreement to develop novel commercial products incorporating Augmenta’s human-derived monoclonal antibodies (mAbs) for potential COVID-19 therapeutics.

Under the terms of the Agreement, both companies will collaborate in a Joint Development Project to develop one or more commercial therapeutics based on, derived from, and/or incorporating Augmenta’s human monoclonal antibodies to potentially treat patients with COVID-19. These products will be developed utilizing TFF Pharmaceuticals’ Thin-Film Freezing technology to manufacture dry powder formulations of these specific mAbs for inhalation delivery directly to the lungs of patients. The Agreement also includes the development of formulations suitable for parenteral administration, where the Thin Film Freezing dry powder formulations can be reconstituted, potentially mitigating the impacts of cold-chain storage and handling. TFF Pharmaceuticals will also have the option to develop two additional Augmenta mAbs for indications other than COVID-19.

Augmenta Bioworks and TFF Pharmaceuticals will allocate patent license rights to their respective technologies to allow each company to jointly commercialize the products developed under the Joint Development Project. The companies have agreed to a 50-50 split of all costs and expenses to further the Joint Development Project and both companies have agreed to the same 50-50 split of all revenues, cash payments and/or future cash payments related to the sale and/or license of the products resulting from the Joint Development Project to a third party.

“This important agreement represents the culmination of many months of work by our scientific team, as we work towards the development of a never-before-achieved formulation of monoclonal antibodies into a dry powder therapeutic,” said Glenn Mattes, CEO, of TFF Pharmaceuticals, Inc. “It is a testament to the remarkable flexibility and capability of our Thin Film Freezing platform and we are eager to develop these potentially breakthrough mAb therapies internally, along with our other programs in Invasive Pulmonary Aspergillosis, solid organ transplant anti-rejection, and botanicals.”

“Confirmed discovery of novel anti-SARS-Cov-2 antibodies in 8 days was an achievement made possible by years of technology development, and a clear indication of the power and potential of our platform,” said Christopher Emig, Ph.D., CEO and Co-Founder of Augmenta Bioworks, Inc. “We are excited to enter this partnership to bring our COVID-19 treatment into clinical development, and are looking forward to the world’s first effective, affordable and scalable antibody therapeutic to mitigate the devastating effects of this disease.”

“We believe the interest in monoclonal-antibody therapeutics for the treatment of COVID-19 is extremely high, with the promise that they will harness the immune system’s natural response to viral invaders,” said Robert O. Williams III, Ph.D., Division Head of the University of Texas at Austin’s Division of Molecular Pharmaceutics and Drug Delivery and inventor of TFF Pharmaceuticals’ Thin Film Freezing technology.

“The challenge

Read more

Sapreme Appoints Miriam Bujny as Chief Development Officer

Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the appointment of Miriam Bujny, Ph.D., as Chief Development Officer. With over ten years of experience in drug discovery, translational science and early stage clinical development, Dr. Bujny will apply her expertise in RNA and antibody therapeutic development to further advance Sapreme’s proprietary endosomal escape platform through preclinical development. Dr. Bujny will be based at Sapreme’s headquarters in Utrecht, The Netherlands, and will report to the CEO.

“Throughout my career, I have seen the limitations of developing promising therapeutic candidates due to the lack of delivery into key cells,” commented Dr. Bujny, Chief Development Officer of Sapreme. “Sapreme is developing a promising platform, that has the ability to improve the delivery and thereby the efficacy for a broad range of macromolecules such as antibody-conjugated toxins and antisense oligonucleotides. I look forward to applying my experience and knowledge toward Sapreme’s mission of developing next-generation macromolecule therapeutics.”

Commenting on the appointment, Guy Hermans, Chief Executive Officer of Sapreme said, “After recently announcing positive preclinical data on our proprietary endosomal escape platform, we are now concentrated on building out our team to accelerate the development of our compounds and identifying the full potential of our platform in the different therapeutic areas. Miriam’s experience in drug discovery and development as well as her demonstrated ability to strategically and operationally lead projects toward the next stage of development will be a valuable asset to us. We welcome Miriam to the team and look forward to working with her.”

Over the last ten years, Dr. Bujny has held leadership positions in various drug discovery and clinical development roles. Prior to joining Sapreme, Miriam worked at ProQR Therapeutics, a Dutch biotech company developing RNA therapies for severe genetic disorders, as Senior Director R&D. During her time at ProQR, she led the early development activities for a novel RNA therapy for Fuchs’ endothelial corneal dystrophy, a common inherited eye disease, from lead candidate optimization toward clinical development preparations. She also headed the Translational Science department and oversaw biomarker and assay development activities across a variety of RNA therapy programs for rare diseases. From 2012 to 2016, she worked in various roles for Janssen, part of the Pharmaceutical Companies of Johnson & Johnson, where she established and headed the predictive biomarker department at the Janssen Prevention Center. Before that, she worked on anti-viral antibody therapy development and contributed to early clinical development as preclinical in vitro lead. Prior to this, Miriam worked at Crucell, before its acquisition by Johnson & Johnson, in the Innovation & Discovery Labs on antibody discovery and engineering.

Dr. Bujny holds a Ph.D. in biochemistry from the University of Bristol with a specialization in endosomal transport. She completed postdoctoral training in the lab of Dr. Xiaowei Zhuang at Harvard University, specializing in developing imaging methods in order to apply them to biomedical questions.

About Sapreme

Sapreme’s mission is to develop next-generation macromolecule therapeutics by

Read more

GoodCell Raises $17.9 Million to Accelerate Development of Its Actionable Health Technology Platform

Capital will fuel continued growth of the company’s IP for measuring genetic variations in cells and scaling its cutting-edge data and analytics platform to track, monitor and support identification of potential health risks

GoodCell (“LifeVault Bio”), the company decoding human health to extend and improve the quality of life through technology powered by science, today announced that it has raised $17.9 million in a preferred equity round. GoodCell intends to use this latest funding to support the company’s IP for detecting and monitoring accumulated genetic variation within blood cells. Financing will also help advance the company’s big data analytics platform to validate novel applications for its health tracking and risk identification solutions through GoodCell Diagnostics and GoodCell’s personal biobanking service.

“COVID-19 has demonstrated the importance of solutions that can help people understand their risks and stay ahead of their health,” said Trevor Perry, Founder and Chief Executive Officer, GoodCell. “We are grateful for a growing investor community that shares our passion for delivering on the promise of personalized healthcare. This latest capital infusion will help us achieve our next stage of development for our platform as we introduce new solutions to the market that change the way individuals, researchers, clinicians and pharmacists predict, identify and monitor disease risk.”

Inherited genetic predisposition to disease has become a fixture of research and clinical care. However, accumulated, or somatic, genetic variations that emerge as a result of age and environmental factors remain a relatively underexplored area of study. A growing body of research suggests that accumulated genetic variations that culminate in the expansion of detrimental variations and cause damage to DNA within blood cells – a phenomenon known as clonal hematopoiesis (CH) – may be linked to higher disease risk. Notably, research continues to bolster linkages between these somatic changes and the aberrant immune response associated with severe COVID-19 cases. These variations have also been correlated to a predisposition toward certain cancers and cardiovascular conditions.

GoodCell, which recently filed patent applications for methods of predicting susceptibility to infectious disease and related methods of treatment, uniquely measures and monitors both inherited and acquired genetic variations in blood stem cells and other nucleated cells in blood over time. Proceeds from this latest raise will support the ongoing buildout of the company’s proprietary data aggregation and analytics technology platform, which aims to decode our cells and harness their insights to advance population and personal health. The funding is also intended to support exploration and development of novel applications for these data streams to support emerging science as it relates to pathogen susceptibility, cell quality, autoimmune and inflammatory disease assessment and more.

Notably, the company’s latest filings informed the development of the GoodCell Pathogen Susceptibility Testing Platform and serve as the foundation for a recently launched three-stage study to investigate COVID-19 in collaboration with New York Blood Center. The resulting research, anticipated in the coming months, is expected to provide important data on COVID-19 risk factors that could ultimately inform the creation of a first-of-its-kind

Read more

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

MELBOURNE, Australia, Oct. 25, 2020 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Cogstate, Ltd. (Headquarters: Melbourne, Australia and New Haven, USA, CEO: Brad O’Connor, “Cogstate”) announced today that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the “Cogstate Brief BatteryTM” (CBB) for use in healthcare and other markets. This global licensing deal is an expansion of an existing partnership executed in August 2019 whereby Eisai secured exclusive development and commercialization rights in Japan for all cognitive function tests developed by Cogstate, including the CBB. Both companies plan to proceed with development globally of CBB as a tool for individuals to self-assess brain performance to support healthy lifestyle choices and preventative measures in daily life, as well as a medical device to aid healthcare professionals in clinical diagnosis decisions.    

Logo
Logo

Developed by Cogstate, the CBB is a scientifically validated digital tool that enables cognitive function self-checks and consists of four tests evaluating psychomotor function, attention, learning and memory, and working memory. In the United States, Europe, Australia, New Zealand and Canada, the CBB has been adapted as a medical device named “CognigramTM” that has achieved marketing authorization by regulators in these jurisdictions and provides informative results for healthcare professionals to support clinical examination to aid in the diagnosis of MCI and dementia.

In its medium-term business plan, EWAY2025, Eisai is aiming to become a “Medico Societal Innovator” (a company that changes society through creating medicines and providing solutions). Eisai is creating next-generation medical remedies focused on the neurology and oncology areas as well as building disease ecosystem platforms, in order to provide environments and solutions including digital solutions for early diagnosis and early treatment.

Cogstate aims to make assessment of brain health as simple, common and informative as assessment of blood pressure. Cogstate’s technology, which is easy to use and available in over 70 languages, is supported by extensive scientific validation, including more than 600 peer reviewed publications. Cogstate technology has been used extensively in clinical trials, including trials conducted by Eisai.

The global agreement between Eisai and Cogstate will allow the two companies to replicate many of the advancements that have already been launched in Japan, where Eisai has developed and launched a new digital tool using the CBB, named “NouKNOWTM” (pronounced “NOH-NOH”), a non-medical device for self-assessment of brain performance (brain health). Eisai is currently investigating the possibility of developing a medical device using the CBB in Japan.

In recent years, various research has demonstrated the possibility that decline in brain performance may be mitigated through major readjustments to lifestyle, such as regular exercise and sleep, a well-balanced diet, and social interaction. However, according to a survey by Eisai, the number of people taking correct preventive actions or habitually performing self-checks of cognitive function

Read more

Trudeau challenges Trump’s claim that vaccine will be available ‘in weeks’, announces $214M for Canadian vaccine development

For more on today’s top stories and the spread of the novel coronavirus across the country, please refer to our live updates below throughout the day, as well as our COVID-19 news hub.

Trudeau says COVID-19 vaccine won’t come before the new year

At a press conference on Friday, Prime Minister Justin Trudeau responded to U.S. President’s Donald Trump’s claim that a viable COVID-19 vaccine could be available in a matter of “weeks,” if not by the end of the year.

“We are hopeful that the vaccines will arrive yesterday, but they won’t,” Trudeau said. “There’s still a number more months of work to do.”

“Reasonable expectation is that vaccines could start to arrive sometime in the new year but even then, there will be smaller amounts of doses that will have to be distributed to priority populations, I think of most vulnerable or our frontline workers.”

The prime minister also said Canada has “an excellent portfolio of vaccine potentials” but stressed that “nobody’s got a vaccine yet.”

“There are still trials going on, there are still a number of companies, some closer than others, but we are waiting to ensure that those vaccines are effective and further, that they will be safe for Canadians,’ Trudeau said. “Nothing will be distributed in Canada until Health Canada is absolutely certain that the safety of Canadians is being properly covered and taken care of.” 

PM looking at Alberta travel pilot project to guide loosening border restriction

The prime minister also commented on yesterday’s announcement that Alberta will begin a pilot project in November, allowing travellers to be tested for COVID-19 upon returning to the province to reduce the required self-isolation time

“We’re interested in seeing the result of this pilot project, but it is only a pilot project,” Trudeau said. “As we move forward into the coming months and perhaps look at loosening some of the border restrictions internationally, we will be able to have data to rely on to make sure that we are first and foremost, keeping Canadian’s safe and controlling the spread of the virus.”

‘This is serious’

When speaking more generally about the COVID-19 situation in Canada, the prime minister stressed to Canadians that the daily case numbers in the country need to be reduced, as Canada saw its highest single-day increase on Thursday, totalling 2,786 cases.

“We have to get these numbers down, this is serious and everybody must do their part,” Trudeau said. “People’s lives are at stake, we can’t afford to be careless or think that this virus will just go away on its own.”

Dr. Theresa Tam, Canada’s chief public health officer, spoke specifically about the increases in outbreaks in long-term care facilities in Canada, including Ontario and Quebec.

“The size of the outbreaks are smaller than in the initial wave,” Dr. Tam identified. “I’m not sure exactly what that means, that could be people are identifying things more rapidly and putting in control measures, and the prevention is better, but

Read more